[Pneumocystis carinii pneumonia during therapy with 2-chlorodeoxyadenosine (2-CDA)].
We report the case of a 70-year-old patient with B-cell chronic lymphocytic leukemia. During therapy with the new purine analog 2-chloro-deoxyadenosine (2-CDA) the patient developed Pneumocystis carinii pneumonia (PCP). Although the mechanism of action of 2-CDA suggests the incidence of opportunistic infections and therefore pneumocystis pneumonia, this is the first case of PCP among 140 patients of the Swiss study of 2-CDA. The mechanism of action of 2-CDA is described and the occurrence of PCP among patients without acquired immunodeficiency syndrome is discussed.
Haberthür
C
C
Departement Innere Medizin, Kantonsspital Basel.
Pless
M
M
Tichelli
A
A
Gratwohl
A
A
Speck
B
B
Betticher
D C
DC
D000368:Aged; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D011020:Pneumonia, Pneumocystis / Q000150:complications*
D017338:Cladribine
Pneumocystis-carinii-Pneumonie unter Therapie mit 2-Chlorodeoxyadenosin (2-CDA).